SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
BrainsWay Ltd. (BRSYF) trades at a trailing P/E of 71.3. Trailing earnings yield is 1.40%. PEG 0.64 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 71.3).
- PEG Ratio 0.64 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.40% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
Overall SharesGrow Score: 63/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BRSYF
Valuation Multiples
P/E (TTM)71.3
Forward P/EN/A
PEG Ratio0.64
Forward PEGN/A
P/B Ratio0.00
P/S Ratio10.16
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.19
Book Value / Share$0.00
Revenue / Share$1.33
FCF / Share$0.00
Yields & Fair Value
Earnings Yield1.40%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.17 |
$11.52M |
$-2.4M |
-20.8% |
| 2017 |
$-0.48 |
$11.15M |
$-7.05M |
-63.3% |
| 2018 |
$-0.39 |
$16.4M |
$-6.48M |
-39.5% |
| 2019 |
$-0.50 |
$23.1M |
$-10.33M |
-44.7% |
| 2020 |
$-0.24 |
$22.06M |
$-5.39M |
-24.4% |
| 2021 |
$-0.21 |
$29.66M |
$-6.46M |
-21.8% |
| 2022 |
$-0.43 |
$27.18M |
$-13.35M |
-49.1% |
| 2023 |
$-0.13 |
$31.79M |
$-4.2M |
-13.2% |
| 2024 |
$0.09 |
$41.02M |
$2.92M |
7.1% |
| 2025 |
$0.19 |
$56.53M |
$8.26M |
14.6% |
